1. Selective delivery of pIC/PPHAffibody decreases the survival of HER2-overexpressing cells.
Selective delivery of pIC/PPHAffibody decreases the survival of HER2-overexpressing cells. A, survival of BT-474, SK-BR-3, MCF-7, and MDA-MB-231 cells treated with pIC/PPHAffibody or pIC/PPCys at the indicated concentrations for 72 hours (***, P < BT-474 vs. MDA-MB-231 or for pIC/PPHAffibody vs. pIC/PPCys). B, internalization of pIC/PPHAffibody into BT-474 and MDA-MB-231 after 2 and 4 hours of treatment (described in Materials and Methods) as shown by confocal microscopy. Pictures were taken at ×10 magnification; scale bar, 4 μm. C, survival of BT-474 and SK-BR-3 cells following treatment with pIC/PPHAffibody or trastuzumab. D, survival of BT-474 trastuzumab-resistant cells following treatment with pIC/PPHAffibody (**, P < μg/mL vs. untreated cells). In A,C, and D, cell survival is presented as the percentage of untreated (UT) cells of the same cell line. Error bars, SD. Representative figures of at least three independent experiments.
Maya Zigler et al. Cancer Immunol Res 2016;4:
©2016 by American Association for Cancer Research